DAY 1
Initial tests suggested fungal infection
The bronchoscopy performed in the ICU suggested
that Yusuf had an IFI.
Based on the bronchoscopy observations, invasive
tracheobronchial aspergillosis with probable
invasive pulmonary aspergillosis was suspected.
Antifungal therapy with Liposomal
Amphotericin B (3 mg/kg/day) was initiated.*,**,†
*Administration of a test dose is advisable before a new course of Liposomal Amphotericin B treatment. Therapy is
usually instituted at a daily dose of 1.0 mg/kg of body weight1. In studies comparing ALiposomal Amphotericin B 3 mg/kg
daily with higher doses (5, 6 or 10 mg/kg daily), it was found that the incidence rates of increased serum creatinine,
hypokalaemia and hypomagnesaemia were notably higher in the high dose groups.
**Please refer to the Summary of Product Characteristics of your chosen treatment prior to prescribing.
†The decision to use Liposomal Amphotericin B at this point in the case was made by the responsible physician, in the
context of the patient's history of liver disease and elevated transaminases on admission, which made other potential
treatments a less appropriate option. This case does not constitute a recommendation for use.
Day 0
ICU admission
Decision point
Results
DAY 1
Initial tests suggested fungal infection
The bronchoscopy performed in the ICU suggested that Yusuf had an IFI.
Based on the bronchoscopy observations, invasive tracheobronchial aspergillosis with probable
invasive pulmonary aspergillosis was suspected.
Antifungal therapy with Liposomal Amphotericin B (3 mg/kg/day) was initiated.*,**,†
*Administration of a test dose is advisable before a new course of Liposomal Amphotericin B treatment. Therapy is usually instituted at a daily dose of 1.0 mg/kg of body weight1. In studies comparing Liposomal Amphotericin B
3 mg/kg daily with higher doses (5, 6 or 10 mg/kg daily), it was found that the incidence rates of increased serum creatinine, hypokalaemia and hypomagnesaemia were notably higher in the high dose groups.
**Please refer to the Summary of Product Characteristics of your chosen treatment prior to prescribing.
†The decision to use Liposomal Amphotericin B at this point in the case was made by the responsible physician, in the context of the patient's history of liver disease and elevated transaminases on admission, which made other potential treatments a less appropriate option.
This case does not constitute a recommendation for use.
Results
DAY 0
ICU Admission
Decision point